Clearside Biomedical, Inc.

Equities

CLSD

US1850631045

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-27 pm EDT			5-day change	1st Jan Change
1.28 ^USD	+5.79%		+11.30%	+9.40%

Jun. 25	Oppenheimer Initiates Clearside Biomedical at Outperform With $5 Price Target	MT
May. 13	HC Wainwright Adjusts Price Target on Clearside Biomedical to $5 From $6, Keeps Buy Rating	MT

CLEARSIDE BIOMEDICAL, INC. : Other Events (form 8-K)

January 05, 2021 at 05:22 pm EST

Item 8.01Other Events.

For the period from October 1, 2020 to January 4, 2021, Clearside Biomedical, Inc. sold 4,497,703 shares of its common stock pursuant to its at-the-market sales agreement with Cowen and Company LLC for net proceeds of $9.4 million.

--------------------------------------------------------------------------------

Latest news about Clearside Biomedical, Inc.

Oppenheimer Initiates Clearside Biomedical at Outperform With $5 Price Target	Jun. 25	MT
HC Wainwright Adjusts Price Target on Clearside Biomedical to $5 From $6, Keeps Buy Rating	May. 13	MT
Transcript : Clearside Biomedical, Inc., Q1 2024 Earnings Call, May 09, 2024	May. 09
Clearside Biomedical, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Clearside Biomedical, Inc Appoints Anthony S. Gibney to its Board of Directors	Apr. 16	CI
Clearside Biomedical Names Victor Chong Chief Medical Officer	Mar. 18	MT
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer	Mar. 18	CI
Wedbush Trims Clearside Biomedical's PT to $4 From $5 After Increased Share Count, Model Adjustments; Maintains Outperform Rating	Mar. 13	MT
Clearside Biomedical, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12	CI
Transcript : Clearside Biomedical, Inc., Q4 2023 Earnings Call, Mar 12, 2024	Mar. 12
Clearside Biomedical, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 12	CI
Clearside Biomedical Shares Decline After Stock Sale by CEO, CFO	Jan. 22	MT
Clearside Biomedical, Inc. Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD	Dec. 14	CI
Transcript : Clearside Biomedical, Inc., Q3 2023 Earnings Call, Nov 13, 2023	Nov. 13
Clearside Biomedical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
BioCryst Pharmaceuticals, Clearside Biomedical Enter Drug Development Collaboration	Nov. 03	MT
Biocryst Pharmaceuticals, Inc. and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside's Proprietary Scs Microinjector	Nov. 03	CI
Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting	23-10-16	CI
Clearside Biomedical, Inc.(NasdaqGM:CLSD) dropped from S&P Global BMI Index	23-09-18	CI
Transcript : Clearside Biomedical, Inc., Q2 2023 Earnings Call, Aug 14, 2023	23-08-14
Clearside Biomedical, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Clearside Biomedical Says Trial Showed Favorable Safety Profile for Macular Degeneration Treatment	23-07-31	MT
Clearside Biomedical Highlights Excellent Safety Profile of CLS-AX and Potential for Extended Duration of Effect in Data Presentation At the American Society of Retina Specialists 41st Annual Scientific Meeting	23-07-31	CI
Transcript : Clearside Biomedical, Inc. - Special Call	23-07-30
Transcript : Clearside Biomedical, Inc. - Special Call	23-07-17

Chart Clearside Biomedical, Inc.

Duration

Period

More charts

Company Profile

Clearside Biomedical, Inc. is a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). The Company's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The Company is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. It developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.

Sector

Biotechnology & Medical Research

Calendar

2024-08-05 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Clearside Biomedical, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.21 USD

Average target price

5.167 USD

Spread / Average Target

+327.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CLEARSIDE BIOMEDICAL, INC.	+9.40%	90.42M
VERTEX PHARMACEUTICALS INCORPORATED	+16.13%	122B
REGENERON PHARMACEUTICALS, INC.	+19.65%	115B
ARGENX SE	+21.22%	26.64B
BIONTECH SE	-23.84%	19.91B
GENMAB A/S	-17.47%	16.32B
WUXI APPTEC CO., LTD.	-45.95%	15.52B
BEIGENE, LTD.	-19.28%	15.49B
SAREPTA THERAPEUTICS, INC.	+63.84%	14.83B
NEUROCRINE BIOSCIENCES, INC.	+1.94%	13.67B

Bio Therapeutic Drugs